[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100565819":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":12,"locations":17,"responsibleParty":35,"collaborators":7,"id":37,"slug":38,"hasResults":39,"nctId":40,"briefTitle":41,"officialTitle":41,"acronym":7,"eligibilityCriteria":42,"healthyVolunteers":39,"sex":43,"minAge":44,"maxAge":7,"enrollmentInfo":45,"targetDuration":7,"studyType":48,"phases":7,"briefSummary":49,"conditions":50,"keywords":54,"overallStatus":20,"whyStopped":7,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":67},{"fullName":5,"class":6},"M.D. Anderson Cancer Center","OTHER",null,[9],{"name":10,"affiliation":5,"role":11},"Y. Jeff Li, MD","PRINCIPAL_INVESTIGATOR",[13],{"name":10,"role":14,"phone":15,"phoneExt":7,"email":16},"CONTACT","713-409-1565","yli61@mdanderson.org",[18],{"facility":19,"status":20,"city":21,"state":22,"zip":23,"country":24,"countryCode":25,"cosmosGeoPoint":26,"geoPoint":31,"contacts":32},"MD Anderson Cancer Center","RECRUITING","Houston","Texas","77030","United States","US",{"type":27,"coordinates":28},"Point",[29,30],-95.36327,29.76328,{"lat":30,"lon":29},[33,34],{"name":10,"role":14,"phone":15,"phoneExt":7,"email":16},{"name":10,"role":11,"phone":7,"phoneExt":7,"email":7},{"type":36,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100565819","a-qualitative-assessment-of-the-severity-and-impact-of-rheumatic-immune-related-adverse-events-following-immune-checkpoint-inhibitor-immunotherapy-100565819",false,"NCT06647134","A Qualitative Assessment of the Severity and Impact of Rheumatic Immune-Related Adverse Events Following Immune Checkpoint Inhibitor Immunotherapy","Inclusion Criteria\n\nThe criteria are:\n\n* Patients aged 18 years and above\n* English (conversational level) speaking, with the ability to give informed consent\n* Patients with a rheumatologist clinician diagnosis of inflammatory arthritis irAE or PMR irAE following ICI therapy\n\nExclusion Criteria\n\n* Acutely life-threatening or worsening cancer\n* Hearing impairment functionally limiting participation in verbal interview","ALL","18 Years",{"count":46,"type":47},20,"ESTIMATED","OBSERVATIONAL","To understand the severity and nature of participants experiences during irAEs following immune checkpoint inhibitor immunotherapy.",[51,52,53],"Arthritis","Polymyalgia Rheumatica","Immune Checkpoint Inhibitors",[55,56,57],"arthritis","polymyalgia rheumatica","immune related adverse events","2026-04-10",{"date":60,"type":61},"2026-04-13","ACTUAL",{"date":63,"type":61},"2024-09-11",{"date":65,"type":47},"2028-03-31",{"name":5,"class":6},1]